Loading

Please wait...

Granix

Generic Name: tbo-filgrastim (TBO fil GRAS tim)
Brand Name: Granix
Physician reviewed Granix patient information - includes Granix description, dosage and directions.
  • Prescription Settings
  • X

Prices and coupons of Granix

Set your location
for drug prices near you

Enter your zip code

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Granix is a man-made form of a protein that stimulates the growth of white blood cells in your body. White blood cells help your body fight against infection. Granix is used to reduce the duration of severe Neutropenia, a lack of certain white blood cells caused by receiving chemoTherapy with certain cancer medications. Granix is for use in adults and children who are least 1 month old. Granix may also be used for purposes not listed in this medication guide. Follow all directions on your medicine label and package. Tell each of your healthcare prOviders about all your medical conditions, allergies, and all medicines you use. Learn more

Granix Side Effects

Granix Side Effects

Note: This document contains side effect information about tbo-filgrastim. Some of the dosage forms listed on this page may not apply to the brand name Granix.

For the Consumer

Applies to tbo-filgrastim: subcutaneous solution

Along with its needed effects, tbo-filgrastim (the active ingredient contained in Granix) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking tbo-filgrastim:

More common

  • Black, tarry stools
  • bleeding gums
  • blood in the urine or stools
  • bone pain
  • fever
  • pinpoint red spots on the skin
  • unusual bleeding or bruising

Rare

  • Chills
  • cough
  • eye pain
  • general feeling of illness
  • headache
  • sore throat
  • unusual tiredness

Incidence not known

  • Blisters or fever sores on the skin
  • bloody or cloudy urine
  • chest pain or tightness
  • difficulty with swallowing
  • dizziness
  • fast heartbeat
  • hives, itching, or skin rash
  • pain in the upper left part of the stomach or at the tip of the left shoulder
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • trouble breathing
  • unusual weakness
  • weight gain

Some side effects of tbo-filgrastim may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Diarrhea
  • pain in the arms or legs

Incidence not known

  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
  • lack or loss of strength

For Healthcare Professionals

Applies to tbo-filgrastim: subcutaneous solution

Cardiovascular

In a clinical trial, thrombocytopenia occurred in 34% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.

Very common (10% or more): Thrombocytopenia (up to 34%)

Frequency not reported: Aortitis, capillary leak syndrome

Gastrointestinal

In a clinical trial, diarrhea occurred in 6% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.

Common (1% to 10%): Diarrhea

Frequency not reported: Vomiting

Musculoskeletal

Common (1% to 10%): Bone pain, extremity pain

Frequency not reported: Myalgia

In a clinical trial, extremity pain occurred in 6% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.

Other

In a clinical trial, pyrexia occurred in 8% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.

Common (1% to 10%): Pyrexia

Postmarketing reports: Asthenia, fatigue

Nervous system

Common (1% to 10%): Headache

In a clinical trial, headache occurred in 6% of pediatric patients (n=50) given 5 mcg/kg subcutaneously once a day starting one day after chemotherapy.

Immunologic

Common (1% to 10%): Anti-drug antibodies to this drug

Hematologic

Frequency not reported: Fatal splenic rupture, leukocytosis, sickle cell disorders

Dermatologic

Frequency not reported: Cutaneous vasculitis

Postmarketing reports: Acute febrile neutrophilic dermatosis, Sweet's syndrome

Oncologic

Frequency not reported: Potential for tumor growth stimulatory effects on malignant cells

Hypersensitivity

Frequency not reported: Serious allergic reactions

Respiratory

Frequency not reported: Acute respiratory distress syndrome

Renal

Frequency not reported: Glomerulonephritis

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.

Source: Drugs.com Granix (www.drugs.com/mtm/granix.html).